WHAT IS CLAIMED IS:

~~1. A method of treating moderate to severe atopic dermatitis comprising:~~

1. ~~administering~~ Use of etrasimod, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of moderate to severe atopic dermatitis in a patient, wherein

the medicament is to be administered to a patient in need thereof;

~~identifying~~ a threshold absolute lymphocyte count (ALC) is to be identified in the patient;

~~ceasing~~ the administration of the medicament is to be ceased ~~the etrasimod, or a pharmaceutically acceptable salt thereof,~~ for an interruption period of time; and

thereafter, ~~ceasing administration for the interruption period of time, continuing to~~ the ~~administer~~ administration of the medicament is to be continued ~~the etrasimod, or a pharmaceutically acceptable salt thereof,~~ for a continuation period of time; and

wherein the patient in need thereof experiences an improvement in moderate to severe atopic dermatitis.

2. The ~~method~~ use of claim 1, wherein the improvement in moderate to severe atopic dermatitis comprises an improvement in validated Investigator Global Assessment (vIGA) score, Eczema Area and Severity Index (EASI) score, or body surface area (BSA) score or in an improvement in a patient-reported outcome assessed using the Dermatology Life Quality Index (DLQI), Patient Oriented Eczema Measure (POEM), or Patient Global Assessment (PGA).

~~3. (Cancelled) The method of any one of the preceding claims, wherein the improvement in moderate to severe atopic dermatitis comprises an improvement in a patient-reported outcome assessed using the Dermatology Life Quality Index (DLQI), Patient Oriented Eczema Measure (POEM), or Patient Global Assessment (PGA).~~

~~4.~~3. The ~~method~~ use of any one of the preceding claims, wherein the ~~etrasimod, or pharmaceutically acceptable salt thereof~~medicament~~,~~ is to be administered at a frequency of once a day during the continuation period of time.

~~5.~~4. The ~~method~~ use of any one of the preceding claims, wherein the ~~etrasimod, or pharmaceutically acceptable salt thereof~~medicament~~,~~ is to be administered in an amount equivalent to 2 mg or in an amount equivalent to 3 mg of etrasimod.

~~6. The method of any one of the preceding claims, wherein the etrasimod, or pharmaceutically acceptable salt thereof, is administered in an amount equivalent to 3 mg of etrasimod.~~

~~7.~~5. The ~~method~~ use of any one of the preceding claims, wherein the threshold ALC is less than 500/mm^3 or between 0.2 x 10e9 cells/L and 0.5 x 10e9 cells/L.

~~8. The method of any one of the preceding claims, wherein the threshold ALC is less than 200/mm^3 or less than 0.2 x 10e9 cells/L.~~

~~9.~~6. The ~~method~~ use of any one of the preceding claims, wherein at least one of the interruption period of time is at least one week or the continuation period of time is at least one month.

~~10. The method of any one of the preceding claims, wherein the interruption period of time is between about one week and about four weeks.~~

~~11. The method of any one of the preceding claims, wherein the continuation period of time is at least one month.~~

~~12. The method of any one of the preceding claims, wherein the moderate to severe atopic dermatitis is moderate atopic dermatitis.~~

~~13. The method of any one of claims 1-11, wherein the moderate to severe atopic dermatitis is severe atopic dermatitis.~~

~~14.~~7. The ~~method~~ use of any one of claims 1-~~11~~6, wherein the patient is diagnosed with

moderate atopic dermatitis and has a vIGA score of 3 or the patient is diagnosed with severe atopic dermatitis and has a vIGA score of 4.

~~15. The method of any one of claims 1-11, wherein the patient is diagnosed with severe atopic dermatitis and has a vIGA score of 4.~~

~~16. The method of any one of claims 1-11, wherein the patient in need thereof comprises a body surface area (BSA) of atopic dermatitis greater than or equal to 10%.~~

~~17.~~8. The ~~method~~ use of any one of the preceding claims, further comprising the step of testing a circulating blood level of lymphocytes in the patient.

~~18. The method of any one of the preceding claims, further comprising testing the circulating blood level of lymphocytes in the patient a subsequent time after the interruption period, identifying a threshold ALC in the patient, and, if the threshold is met, continuing to cease treatment.~~

~~19.~~9. ~~A method of treating moderate to severe atopic dermatitis comprising:~~

~~administering etrasimod, or a pharmaceutically acceptable salt thereof, to a patient in need thereof;~~Use of etrasimod, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of moderate to severe atopic dermatitis in a patient, wherein

the medicament is to be administered to a patient in need thereof;

~~monitoring~~ the patient is to be monitored for one or more infections after administration of the ~~etrasimod or a pharmaceutically acceptable salt thereof~~medicament;

the administration of the medicament is to be ceased for an interruption period of time; and

thereafter, the administration of the medicament is to be continued for a continuation period of time;

~~ceasing administration of the etrasimod, or a pharmaceutically acceptable salt thereof, for an interruption period of time;~~

~~after ceasing administration for the interruption period of time, continuing to administer the etrasimod, or a pharmaceutically acceptable salt thereof, for a continuation period of time;~~

wherein the ~~method~~ treatment is therapeutically effective ~~to treat~~for moderate to severe atopic dermatitis.

~~20.~~10. The ~~method~~ use of claim ~~19~~, wherein the ~~etrasimod, or pharmaceutically acceptable salt thereof~~medicament~~,~~ is to be administered at a frequency of once a day.

~~21. The method of claim 19 or 20, wherein the etrasimod, or pharmaceutically acceptable salt thereof, is administered at a frequency of once a day during the continuation period of time.~~

~~22.~~11. The ~~method~~ use of any one of claims ~~19-21~~10, wherein the etrasimod, or pharmaceutically acceptable salt thereof, is to be administered in an amount equivalent to 2 mg or 3 mg of etrasimod.

~~23. The method of any one of claims 19-21, wherein the etrasimod, or pharmaceutically acceptable salt thereof, is administered in an amount equivalent to 3 mg of etrasimod.~~

~~24.~~12. The ~~method~~ use of any one of claims ~~19-23~~11, wherein at least one of the interruption period of time is at least one week or the continuation period of time is at least one month.

~~25. The method of any one of claims 19-23, wherein the interruption period of time is between about one week and about four weeks.~~

~~26. The method of any one of claims 19-25, wherein the continuation period of time is at least one month.~~

~~27. The method of any one of claims 19-26, wherein the moderate to severe atopic dermatitis is moderate atopic dermatitis.~~

~~28. The method of any one of claims 19-26, wherein the moderate to severe atopic dermatitis is severe atopic dermatitis.~~

~~29.~~13. The ~~method~~ use of any one of claims ~~1~~9-12~~26~~, where in the patient is diagnosed with moderate atopic dermatitis and a vIGA score of 3 or is diagnosed with severe atopic dermatitis and has a vIGA score of 4.

~~30. The method of any one of claims 19-26, where in the patient is diagnosed with severe atopic dermatitis and has a vIGA score of 4.~~

~~31.~~14. The ~~method~~ use of any one of claims ~~1~~9-~~26~~13, wherein the patient in need thereof comprises a body surface area (BSA) of atopic dermatitis greater than or equal to 10%.

~~32.~~15. The ~~method~~ use of any one of claims ~~1~~9-~~31~~14, further comprising the step of monitoring the patient for infection a subsequent time after the interruption period, and, if an infection is identified, continuing to cease treatment.

~~33.~~16. The ~~method~~ use of any one of claims ~~1~~9-15~~32~~, wherein the one or more infections is selected from urinary tract infection, ear infection, common cold, diptheria, E. coli, giardiasis, HIV/AIDS, mononucleosis, influenza, lyme disease, measles, meningitis, mumps, pneumonia, salmonella infections, respiratory infections, shingles, herpes, tuberculosis, viral hepatitis, or COVID-19.

~~34.~~17. The ~~method~~use of claim 1, further comprising~~A method of treating moderate to severe atopic dermatitis comprising~~:

~~administering etrasimod, or a pharmaceutically acceptable salt thereof, to a patient in need thereof;~~

the step of testing a circulating blood level of lymphocytes in the patient; and

~~identifying a threshold absolute lymphocyte count (ALC) in the patient;~~

~~ceasing administration of the etrasimod, or a pharmaceutically acceptable salt thereof, for an~~ wherein the interruption period of time ~~of~~ is one day to four weeks~~;~~.

~~after ceasing administration for the interruption period of time, continuing to administer the etrasimod, or a pharmaceutically acceptable salt thereof, for a continuation period of time;~~

~~wherein the patient in need thereof experiences an improvement in moderate to severe atopic dermatitis.~~

~~35. The method of claim 34, wherein the etrasimod, or pharmaceutically acceptable salt thereof, wherein the improvement to moderate to severe atopic dermatitis comprises an improvement in validated Investigator Global Assessment (vIGA) score, Eczema Area and Severity Index (EASI) score, or body surface area (BSA) score.~~

~~36. The method of claim 34 or 35, wherein the improvement in moderate to severe atopic dermatitis comprises an improvement in a patient-reported outcome assessed using the Dermatology Life Quality Index (DLQI), Patient Oriented Eczema Measure (POEM), or Patient Global Assessment (PGA).~~

~~37. The method of any one of claims 34-36, wherein the moderate to severe atopic dermatitis is moderate atopic dermatitis.~~

~~38. The method of any one of claims 34-36, wherein the moderate to severe atopic dermatitis is severe atopic dermatitis.~~

~~39.~~18. ~~A method of treating or ameliorating at least one symptom or indication of atopic dermatitis in an individual in need thereof, comprising: administering to the individual in need thereof~~ Use of a pharmaceutical dosage form comprising a therapeutically effective amount of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[*b*]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or amelioration of at least one symptom or indication of atopic dermatitis in an individual, wherein the ~~Compound 1 or pharmaceutically acceptable salt thereof~~medicament is to be administered in an amount equivalent to more than 2 mg to the individual in need thereof.

~~40. The method of claim 39, wherein the Compound 1, or pharmaceutically acceptable salt thereof, is administered in an amount equivalent to 3 mg.~~

~~41. The method of claim 39 or 40, wherein the improvement to moderate to severe atopic dermatitis comprises an improvement in validated Investigator Global Assessment (vIGA) score, Eczema Area and Severity Index (EASI) score, or body surface area (BSA) score.~~

~~42. The method of any one of claims 39-41, wherein the improvement to moderate to severe atopic dermatitis comprises an improvement in a patient-reported outcome assessed using the Dermatology Life Quality Index (DLQI), Patient Oriented Eczema Measure (POEM), or Patient Global Assessment (PGA).~~

~~43.~~19. The ~~method~~ use of ~~any one of~~ claim~~s~~ ~~39-42~~18, wherein an~~the~~ improvement to moderate to severe atopic dermatitis comprises an improvement in pruritus.

~~44. The method of any one of claims 39-43, wherein the Compound 1, or pharmaceutically acceptable salt thereof, is administered at a frequency of once a day.~~

~~45. The method of any one of claims 39-44, wherein the atopic dermatitis is moderate to severe atopic dermatitis.~~

~~46. The method of claim 45, wherein the moderate to severe atopic dermatitis is moderate atopic dermatitis.~~

~~47. The method of claim 45, wherein the moderate to severe atopic dermatitis is severe atopic dermatitis.~~

~~48.~~20. The ~~method~~ use of claim ~~45~~19, wherein the patient is diagnosed with moderate atopic dermatitis and has a vIGA score of 3 or the patient is diagnosed with severe atopic dermatitis and has a vIGA score of 4.

~~49. The method of claims 45, wherein the patient is diagnosed with severe atopic dermatitis and has a vIGA score of 4.~~

~~50. The method of claim 45, wherein the patient in need thereof comprises a body surface area (BSA) of atopic dermatitis greater than or equal to 10%.~~